Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an update.
Shanghai Fosun Pharmaceutical has successfully completed the issuance of its first tranche of medium-term notes for 2025, valued at RMB 0.5 billion. These notes, aimed at supporting scientific and technological innovation, have a fixed interest rate of 3.10% and are set to mature in two years, with the Bank of Shanghai as the leading underwriter.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. The company focuses on scientific and technological innovation within the healthcare sector.
YTD Price Performance: 10.20%
Average Trading Volume: 5,648
Technical Sentiment Signal: Sell
Current Market Cap: $8.07B
For a thorough assessment of 2196 stock, go to TipRanks’ Stock Analysis page.